{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:47:56Z","timestamp":1792608476482,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.mayocp.2017.11.013","type":"journal-article","created":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T11:02:55Z","timestamp":1516791775000},"page":"155-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":111,"title":["Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia\u2013Related Epistaxis and Gastrointestinal Bleeding"],"prefix":"10.1016","volume":"93","author":[{"given":"Vivek N.","family":"Iyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh R.","family":"Apala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibek S.","family":"Pannu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Brinjikji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Leise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick S.","family":"Kamath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kebede H.","family":"Begna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Cartin-Ceba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary M.","family":"DuBrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Krowka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin K.","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv K.","family":"Pruthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell R.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mayocp.2017.11.013_bib1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1572-0241.2003.07185.x","article-title":"Diagnosis and management of gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia","volume":"98","author":"Longacre","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.mayocp.2017.11.013_bib2","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1513\/AnnalsATS.201603-200OC","article-title":"High rates of bleeding complications among hospitalized patients with hereditary hemorrhagic telangiectasia in the United States","volume":"13","author":"Brinjikji","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"8","key":"10.1016\/j.mayocp.2017.11.013_bib3","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1634\/theoncologist.2009-0317","article-title":"Bevacizumab","volume":"15","author":"Kazazi-Hyseni","year":"2010","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.mayocp.2017.11.013_bib4","first-page":"591","article-title":"Plasma level and tissue expression of angiogenic factors in patients with hereditary hemorrhagic telangiectasia","volume":"15","author":"Sadick","year":"2005","journal-title":"Int J Mol Med"},{"issue":"6","key":"10.1016\/j.mayocp.2017.11.013_bib5","first-page":"818","article-title":"Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression","volume":"90","author":"Sadick","year":"2005","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.mayocp.2017.11.013_bib6","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jama.2012.250","article-title":"Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output","volume":"307","author":"Dupuis-Girod","year":"2012","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.mayocp.2017.11.013_bib7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/MAJ.0b013e3182429866","article-title":"Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab","volume":"343","author":"Fleagle","year":"2012","journal-title":"Am J Med Sci"},{"issue":"3","key":"10.1016\/j.mayocp.2017.11.013_bib8","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/MCG.0b013e3182688d49","article-title":"Bevacizumab as rescue treatment for severe recurrent gastrointestinal bleeding in hereditary hemorrhagic telangiectasia","volume":"47","author":"Lupu","year":"2013","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"2","key":"10.1016\/j.mayocp.2017.11.013_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/jmg.2009.069013","article-title":"HHT Foundation International - Guidelines Working Group. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia","volume":"48","author":"Faughnan","year":"2011","journal-title":"J\u00a0Med Genet"},{"issue":"5","key":"10.1016\/j.mayocp.2017.11.013_bib10","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/lary.25669","article-title":"The minimal important difference of the Epistaxis Severity Score in hereditary hemorrhagic telangiectasia","volume":"126","author":"Yin","year":"2016","journal-title":"Laryngoscope"},{"issue":"4","key":"10.1016\/j.mayocp.2017.11.013_bib11","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/lary.20818","article-title":"An Epistaxis Severity Score for hereditary hemorrhagic telangiectasia","volume":"120","author":"Hoag","year":"2010","journal-title":"Laryngoscope"},{"issue":"2","key":"10.1016\/j.mayocp.2017.11.013_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2500\/ar.2014.5.0091","article-title":"Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia","volume":"5","author":"Thompson","year":"2014","journal-title":"Allergy Rhinol (Providence)"},{"issue":"10","key":"10.1016\/j.mayocp.2017.11.013_bib13","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2174\/138161206776361255","article-title":"Treatment of recurrent epistaxis in HHT","volume":"12","author":"Geisthoff","year":"2006","journal-title":"Curr Pharm Des"},{"issue":"4","key":"10.1016\/j.mayocp.2017.11.013_bib14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2500\/105065899782102890","article-title":"A\u00a0treatment algorithm for the management of epistaxis in hereditary hemorrhagic telangiectasia","volume":"13","author":"Lund","year":"1999","journal-title":"Am J Rhinol"},{"issue":"25","key":"10.1016\/j.mayocp.2017.11.013_bib15","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJM199406233302504","article-title":"Brief report: treatment of bleeding in hereditary hemorrhagic telangiectasia with aminocaproic acid","volume":"330","author":"Saba","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2017.11.013_bib16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.7326\/0003-4819-109-2-171_1","article-title":"Hereditary hemorrhagic telangiectasia and danazol","volume":"109","author":"Haq","year":"1988","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.mayocp.2017.11.013_bib17","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1160\/TH06-07-0373","article-title":"Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1\/endoglin pathway in endothelial cells","volume":"97","author":"Fernandez-L","year":"2007","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.mayocp.2017.11.013_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0001-6519(07)74897-5","article-title":"Treatment of epistaxes in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease) with tranexamic acid [in Spanish]","volume":"58","author":"Morales-Angulo","year":"2007","journal-title":"Acta Otorrinolaringol Esp"},{"issue":"9","key":"10.1016\/j.mayocp.2017.11.013_bib19","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/jth.12654","article-title":"Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease","volume":"12","author":"Gaillard","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"10.1016\/j.mayocp.2017.11.013_bib20","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1160\/TH09-07-0425","article-title":"Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells","volume":"103","author":"Albi\u00f1ana","year":"2010","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.mayocp.2017.11.013_bib21","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/lary.20065","article-title":"Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial","volume":"119","author":"Yaniv","year":"2009","journal-title":"Laryngoscope"},{"issue":"2","key":"10.1016\/j.mayocp.2017.11.013_bib22","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4193\/Rhino09.201","article-title":"Anti-estrogen therapy for hereditary hemorrhagic telangiectasia\u2014a long-term clinical trial","volume":"49","author":"Yaniv","year":"2011","journal-title":"Rhinology"},{"issue":"4","key":"10.1016\/j.mayocp.2017.11.013_bib23","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/00005537-200404000-00021","article-title":"Hormonal and antihormonal therapy for epistaxis in hereditary hemorrhagic telangiectasia","volume":"114","author":"Jameson","year":"2004","journal-title":"Laryngoscope"},{"issue":"5","key":"10.1016\/j.mayocp.2017.11.013_bib24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/alr.21484","article-title":"Prospective randomized trial of sclerotherapy vs standard treatment for epistaxis due to hereditary hemorrhagic telangiectasia","volume":"5","author":"Boyer","year":"2015","journal-title":"Int Forum Allergy Rhinol"},{"issue":"4","key":"10.1016\/j.mayocp.2017.11.013_bib25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/alr.20053","article-title":"Office-based sclerotherapy for recurrent epistaxis due to hereditary hemorrhagic telangiectasia: a pilot study","volume":"1","author":"Boyer","year":"2011","journal-title":"Int Forum Allergy Rhinol"},{"issue":"1","key":"10.1016\/j.mayocp.2017.11.013_bib26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4193\/Rhino11.211","article-title":"Local sclerotherapy with polydocanol (Aethoxysklerol\u00ae) for the treatment of epistaxis in Rendu-Osler-Weber or hereditary hemorrhagic telangiectasia (HHT): 15 years of experience","volume":"50","author":"Morais","year":"2012","journal-title":"Rhinology"},{"issue":"1","key":"10.1016\/j.mayocp.2017.11.013_bib27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1017\/S0022215100136370","article-title":"A\u00a0retrospective study of the role of the argon laser in the management of epistaxis secondary to hereditary haemorrhagic telangiectasia","volume":"111","author":"Lennox","year":"1997","journal-title":"J\u00a0Laryngol Otol"},{"issue":"1","key":"10.1016\/j.mayocp.2017.11.013_bib28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/194589240602000116","article-title":"New classification of nasal vasculature patterns in hereditary hemorrhagic telangiectasia","volume":"20","author":"Mahoney","year":"2006","journal-title":"Am J Rhinol"},{"issue":"10","key":"10.1016\/j.mayocp.2017.11.013_bib29","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s00405-004-0911-0","article-title":"Management of epistaxis in hereditary hemorrhagic telangiectasia by Nd:YAG laser and quality of life assessment using the HR-QoL questionnaire","volume":"262","author":"Karapantzos","year":"2005","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"12","key":"10.1016\/j.mayocp.2017.11.013_bib30","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00405-011-1677-9","article-title":"Efficiency of laser treatment in patients with hereditary hemorrhagic telangiectasia","volume":"268","author":"J\u00f8rgensen","year":"2011","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"8","key":"10.1016\/j.mayocp.2017.11.013_bib31","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/alr.21328","article-title":"Comparison of electrosurgical plasma coagulation and potassium-titanyl-phosphate laser photocoagulation for treatment of hereditary hemorrhagic telangiectasia-related epistaxis","volume":"4","author":"Luk","year":"2014","journal-title":"Int Forum Allergy Rhinol"},{"issue":"4, pt 1","key":"10.1016\/j.mayocp.2017.11.013_bib32","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00005537-199804000-00028","article-title":"Angiographic embolization for epistaxis: a review of 114 cases","volume":"108","author":"Tseng","year":"1998","journal-title":"Laryngoscope"},{"issue":"1","key":"10.1016\/j.mayocp.2017.11.013_bib33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/019459989411100110","article-title":"Angiographic embolization for the treatment of epistaxis: a review of 108 cases","volume":"111","author":"Elden","year":"1994","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"4","key":"10.1016\/j.mayocp.2017.11.013_bib34","first-page":"247","article-title":"Treatment of severe epistaxis by superselective embolization: a review of 22 cases","volume":"125","author":"Ricci","year":"2004","journal-title":"Rev Laryngol Otol Rhinol (Bord)"},{"issue":"5","key":"10.1016\/j.mayocp.2017.11.013_bib35","first-page":"885","article-title":"Endovascular treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia","volume":"28","author":"Layton","year":"2007","journal-title":"AJNR Am J Neuroradiol"},{"issue":"6","key":"10.1016\/j.mayocp.2017.11.013_bib36","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1007\/s00270-011-0155-5","article-title":"Endovascular treatment of epistaxis: indications, management, and outcome","volume":"34","author":"Strach","year":"2011","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"8","key":"10.1016\/j.mayocp.2017.11.013_bib37","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1258\/ar.2011.110132","article-title":"Epistaxis in patients with hereditary hemorrhagic telangiectasia treated with selective arterial embolization","volume":"52","author":"Trojanowski","year":"2011","journal-title":"Acta Radiol"},{"issue":"2","key":"10.1016\/j.mayocp.2017.11.013_bib38","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1024\/0301-1526\/a000253","article-title":"Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT)","volume":"42","author":"Chavan","year":"2013","journal-title":"Vasa"},{"issue":"2","key":"10.1016\/j.mayocp.2017.11.013_bib39","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/01.mlg.0000154754.39797.43","article-title":"Outcome of septal dermoplasty in patients with hereditary hemorrhagic telangiectasia","volume":"115","author":"Fiorella","year":"2005","journal-title":"Laryngoscope"},{"issue":"2","key":"10.1016\/j.mayocp.2017.11.013_bib40","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2500\/ajr.2008.22.3145","article-title":"The impact of septodermoplasty and potassium-titanyl-phosphate (KTP) laser therapy in the treatment of hereditary hemorrhagic telangiectasia-related epistaxis","volume":"22","author":"Harvey","year":"2008","journal-title":"Am J Rhinol"},{"issue":"6","key":"10.1016\/j.mayocp.2017.11.013_bib41","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.otohns.2008.01.005","article-title":"Long-term complications of septal dermoplasty in patients with hereditary hemorrhagic telangiectasia","volume":"138","author":"Levine","year":"2008","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"1","key":"10.1016\/j.mayocp.2017.11.013_bib42","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/194589240501900113","article-title":"The effect of treatment for epistaxis secondary to hereditary hemorrhagic telangiectasia","volume":"19","author":"Hitchings","year":"2005","journal-title":"Am J Rhinol"},{"issue":"5","key":"10.1016\/j.mayocp.2017.11.013_bib43","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2500\/ajra.2012.26.3809","article-title":"The Young's procedure for severe epistaxis from hereditary hemorrhagic telangiectasia","volume":"26","author":"Richer","year":"2012","journal-title":"Am J Rhinol Allergy"},{"issue":"4","key":"10.1016\/j.mayocp.2017.11.013_bib44","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/alr.21099","article-title":"Management of severe epistaxis after Young's procedure: a case report","volume":"3","author":"Ting","year":"2013","journal-title":"Int Forum Allergy Rhinol"},{"issue":"11","key":"10.1016\/j.mayocp.2017.11.013_bib45","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1017\/S0022215112001806","article-title":"Reversal of Young's procedure in hereditary haemorrhagic telangiectasia","volume":"126","author":"Oozeer","year":"2012","journal-title":"J\u00a0Laryngol Otol"},{"issue":"9","key":"10.1016\/j.mayocp.2017.11.013_bib46","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.2016.11724","article-title":"Effect of topical intranasal therapy on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia: a randomized clinical trial","volume":"316","author":"Whitehead","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.mayocp.2017.11.013_bib47","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/hed.23655","article-title":"Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial","volume":"37","author":"Riss","year":"2015","journal-title":"Head Neck"},{"issue":"3","key":"10.1016\/j.mayocp.2017.11.013_bib48","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/lary.21345","article-title":"Safety of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis","volume":"121","author":"Chen","year":"2011","journal-title":"Laryngoscope"},{"issue":"3","key":"10.1016\/j.mayocp.2017.11.013_bib49","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/lary.22501","article-title":"Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy","volume":"122","author":"Karnezis","year":"2012","journal-title":"Laryngoscope"},{"issue":"2","key":"10.1016\/j.mayocp.2017.11.013_bib50","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00405-011-1721-9","article-title":"A\u00a0retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia","volume":"269","author":"Rohrmeier","year":"2012","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"6","key":"10.1016\/j.mayocp.2017.11.013_bib51","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/lary.23303","article-title":"Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose","volume":"122","author":"Dheyauldeen","year":"2012","journal-title":"Laryngoscope"},{"key":"10.1016\/j.mayocp.2017.11.013_bib52","first-page":"2011","article-title":"Successful treatment of bleeding gastro-intestinal angiodysplasia in hereditary haemorrhagic telangiectasia with thalidomide","author":"Alam","year":"2011","journal-title":"BMJ Case Rep"},{"issue":"8","key":"10.1016\/j.mayocp.2017.11.013_bib53","first-page":"1114","article-title":"Successful treatment of thalidomide for recurrent bleeding due to gastric angiodysplasia in hereditary hemorrhagic telangiectasia","volume":"17","author":"Wang","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"12","key":"10.1016\/j.mayocp.2017.11.013_bib54","doi-asserted-by":"crossref","first-page":"792","DOI":"10.4240\/wjgs.v8.i12.792","article-title":"Bevacizumab and gastrointestinal bleeding in hereditary hemorrhagic telangiectasia","volume":"8","author":"Ou","year":"2016","journal-title":"World J Gastrointest Surg"},{"issue":"1","key":"10.1016\/j.mayocp.2017.11.013_bib55","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3121\/cmr.2013.1205","article-title":"Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia","volume":"13","author":"Epperla","year":"2015","journal-title":"Clin Med Res"},{"issue":"3","key":"10.1016\/j.mayocp.2017.11.013_bib56","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1080\/21645515.2015.1011960","article-title":"Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia","volume":"11","author":"Kochanowski","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.mayocp.2017.11.013_bib57","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/ajmg.a.35309","article-title":"Quality of life in patients with hereditary hemorrhagic telangiectasia in Norway: a population based study","volume":"158A","author":"Geirdal","year":"2012","journal-title":"Am J Med Genet A"},{"issue":"10","key":"10.1016\/j.mayocp.2017.11.013_bib58","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s11136-004-7865-y","article-title":"Health-related quality of life in a rare disease: hereditary hemorrhagic telangiectasia (HHT) or Rendu-Osler-Weber disease","volume":"13","author":"Pasculli","year":"2004","journal-title":"Qual Life Res"},{"issue":"11","key":"10.1016\/j.mayocp.2017.11.013_bib59","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/alr.21374","article-title":"The effects of epistaxis on health-related quality of life in patients with hereditary hemorrhagic telangiectasia","volume":"4","author":"Merlo","year":"2014","journal-title":"Int Forum Allergy Rhinol"},{"issue":"21","key":"10.1016\/j.mayocp.2017.11.013_bib60","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.2007.11.5113","article-title":"Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?","volume":"25","author":"van Heeckeren","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"3, pt 2","key":"10.1016\/j.mayocp.2017.11.013_bib61","first-page":"H1054","article-title":"VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells","volume":"274","author":"Hood","year":"1998","journal-title":"Am J Physiol"},{"issue":"11","key":"10.1016\/j.mayocp.2017.11.013_bib62","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1161\/01.ATV.17.11.2793","article-title":"Vascular endothelial growth factor\/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium","volume":"17","author":"Horowitz","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"}],"updated-by":[{"DOI":"10.1016\/j.mayocp.2018.02.007","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000}}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619617308388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619617308388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T01:38:33Z","timestamp":1603676313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619617308388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0025619617308388"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2017.11.013","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.mayocp.2018.02.007","asserted-by":"object"}]},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia\u2013Related Epistaxis and Gastrointestinal Bleeding","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2017.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}